Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world safety and effectiveness of Rezvilutamide in prostate cancer
ChiCTR2500102249Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Qinghai University
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rezvilutamide in prostate cancer (PCa), sponsored by Affiliated Hospital of Qinghai University. Primary endpoint: Safety. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2500102249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102249.